BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Merck & Co. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Merck & Co.'s drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06448312-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06448312)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Pembro
 lizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lun
 g Cancer\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06448312
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Chemot
 herapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1
  Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468697-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT05468697)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus B
 elzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (
 MK-6482-024/LITESPARK-024)\nEstimated primary completion: 22 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05468697
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631262-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05631262)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 Monotherapy i
 n Selected Subjects With Advanced Solid Tumors\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05631262
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06081959)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of SKB264 for Locally Advanced\, Recurrent or Metas
 tatic HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06081959
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan i
 n Combination With Pembrolizumab for Participants With Metastatic Non-smal
 l Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum
 or Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary completi
 on: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05609968
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241185-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04241185)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Efficacy and Safety of Pembrol
 izumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Al
 one in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)\nEs
 timated primary completion: 31 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04241185
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767513-1081@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07767513)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a
 ) and High Risk of Cardiovascular Events\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 67513
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03407144-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03407144)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Safety and Efficacy of Pembrol
 izumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymph
 oma (MK-3475-667/KEYNOTE-667)\nEstimated primary completion: 12 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT034071
 44
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486960-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07486960)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: Study to Evaluate Tulisokibart 
 in Adults With Psoriatic Arthritis (MK-7240-015)\nEstimated primary comple
 tion: 17 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07486960
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03634540-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03634540)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Trial of Belzutifan (PT2977\, MK-6482) in Combination With Cabozantinib 
 in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)\nEs
 timated primary completion: 26 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03634540
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270525-1526@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Ohtuvayre (ensifentrine): Phase 2 readout est. (NCT05270525)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 2\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Effect of Ensifentrine (MK-5884/RPL554) on Sputum Mar
 kers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5
 884-023/RPL554-CO-207)\nEstimated primary completion: 1 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ensifentrine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05270525
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04976634-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04976634)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Pembrolizumab P
 lus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016
 )\nEstimated primary completion: 22 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04976634
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133633-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07133633)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Study of Tulisokibar
 t (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)\nE
 stimated primary completion: 29 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07133633
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06279364)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of SKB264 Versus Investigator's Choice Chemotherapy in Patients With U
 nresectable Recurrent or Metastatic Triple-Negative Breast Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06279364
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305767-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Intismeran Autogene: Phase 1/2 readout est. (NCT06305767)
DESCRIPTION:Intismeran Autogene\, phase 1/2.\nStudy: A Clinical Study of In
 tismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladde
 r Cancer (V940-005/INTerpath-005)\nEstimated primary completion: 23 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/intismeran-auto
 gene#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06305767
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401788-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03401788)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Phase 2 Study of Belzutifan (PT2977\, MK-6482) for the Treatment of Von 
 Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482
 -004)\nEstimated primary completion: 29 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03401788
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04145622-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04145622)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: Study of Ifinatamab 
 Deruxtecan (DS-7300a\, I-DXd) in Participants With Advanced Solid Malignan
 t Tumors\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04145622
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-2028@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Me
 tastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06909825
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06670196)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Osimertinib Versus Osimerti
 nib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\, L
 ocally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06670196
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02628067)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Study of Pem
 brolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-1
 58/KEYNOTE-158)\nEstimated primary completion: 4 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02628067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428396-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT06428396)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Study of Belzutifan (MK
 -6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-02
 9/LITESPARK-029)\nEstimated primary completion: 5 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06428396
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by P
 embrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Can
 cer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion: 5 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0438
 0636
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06074588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previous
 ly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (
 NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\nEst
 imated primary completion: 10 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06074588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624554-11239@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05624554)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
 CLL/SLL) Without TP53 Aberrations (MK-1026-008\, BELLWAVE-008)\nEstimated 
 primary completion: 19 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05624554
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173987-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05173987)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Study of Pembrolizumab (MK-347
 5) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Rec
 urrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
 \nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05173987
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845814-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05845814)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/
 - Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mU
 C) (MK-3475-04B/KEYMAKER-U04)\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05845814
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: A Study to Evaluate Investigational Agents With or Without Pembro
 lizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previous
 ly Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Deat
 h Ligand 1 (PD-L1) Treatment (MK-3475-06B)\nEstimated primary completion: 
 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05319730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405151-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270612
DTEND;VALUE=DATE:20270613
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07405151)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Trial of Ifinatamab Deruxtecan in People With 
 Advanced Esophageal Cancer (MK-3475-06F)\nEstimated primary completion: 12
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07405151
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308106-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SKB571: Phase 2 readout est. (NCT07308106)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07308106
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07071337)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SKB264 Versus Investigator's Choice of Chemoth
 erapy in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metas
 tatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07071337
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159763-11242@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:MK-1406: Phase 3 readout est. (NCT07159763)
DESCRIPTION:MK-1406\, phase 3.\nStudy: A Study to Evaluate the Safety and E
 fficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ
 .3.06)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/mk-1406#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07159763
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Pembrolizumab\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and 
 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician'
 s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or M
 etastatic Breast Cancer (MK-2870-010)\nEstimated primary completion: 11 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 312176
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079879-2890@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06079879)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (
 BAT) in Participants With Essential Thrombocythemia and an Inadequate Resp
 onse or Intolerance of Hydroxyurea (MK-3543-006)\nEstimated primary comple
 tion: 14 July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 omedemstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06079879
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study of I-DXd in Combination With Atezolizumab With or Without Car
 boplatin as First-Line Induction or Maintenance in Subjects With Extensive
  Stage-Small Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completio
 n: 20 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifin
 atamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06362252
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044297-1010@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07044297)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Clinical Study of MK-852
 7 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)\nEs
 timated primary completion: 22 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07044297
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222488-11234@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT07222488)
DESCRIPTION:MK-3120\, phase 1/2\, Bladder Cancer.\nStudy: A Clinical Study 
 of MK-3120 in People With Bladder Cancer (MK-3120-003)\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/mk-3120#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07222488
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225959-11242@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:MK-1406: Phase 2 readout est. (NCT07225959)
DESCRIPTION:MK-1406\, phase 2.\nStudy: A Study of Annual Doses of MK-1406/C
 D388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)\nEstimated primary comp
 letion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /mk-1406#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07225959
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891066-965@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Islatravir: Phase 2 readout est. (NCT06891066)
DESCRIPTION:Islatravir\, phase 2\, HIV.\nStudy: A Study of Islatravir (ISL)
  and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults
  With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)\nEstimate
 d primary completion: 10 August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/islatravir#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06891066
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07329322)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osi
 mertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564466-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SKB571: Phase 2 readout est. (NCT07564466)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Study of SKB571 in Participants Wit
 h Gastrointestinal Tumors\nEstimated primary completion: 31 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07564466
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03162536-11239@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270917
DTEND;VALUE=DATE:20270918
SUMMARY:Nemtabrutinib: Phase 1/2 readout est. (NCT03162536)
DESCRIPTION:Nemtabrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Ref
 ractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)\nEstimated prim
 ary completion: 17 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03162536
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559150-1526@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Ohtuvayre (ensifentrine): Phase 2 readout est. (NCT06559150)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 2.\nStudy: A Phase II Study of
  Ensifentrine in Non-Cystic Fibrosis Bronchiectasis\nEstimated primary com
 pletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ensifentrine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06559150
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With S
 tandard of Care in Participants With Relapsed or Refractory Diffuse Large 
 B-Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilov
 ertamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05139017
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456346-2890@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06456346)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: Bome
 demstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)\nEstima
 ted primary completion: 28 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06456346
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614984-1081@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07614984)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Clinical Trial of MK-7262 and Enlicitide in Participants With High
  Lipoprotein(a) (MK-7262-004)\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07614984
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-1010@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07071623)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Study of MK-8527 to Prev
 ent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)\nEstimated p
 rimary completion: 18 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071623
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895524-75@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271019
DTEND;VALUE=DATE:20271020
SUMMARY:MK-8690: Phase 2 readout est. (NCT07895524)
DESCRIPTION:MK-8690\, phase 2\, Rheumatoid Arthritis.\nStudy: A Clinical Tr
 ial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)\nEs
 timated primary completion: 19 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mk-8690#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07895524
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Metastatic Castration-Resistant Pro
 state Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination Therapi
 es in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE
 -365)\nEstimated primary completion: 22 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463183-75@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:MK-8690: Phase 2 readout est. (NCT07463183)
DESCRIPTION:MK-8690\, phase 2\, Ulcerative Colitis.\nStudy: A Study to Eval
 uate Efficacy and Safety of MK-8690 in Participants With Moderately to Sev
 erely Active Ulcerative Colitis (MK-8690-002)\nEstimated primary completio
 n: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 k-8690#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07463183
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Placebo-controlled\, Study of 
 Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembroliz
 umab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small 
 Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary co
 mpletion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04624204
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-11235@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Opevesostat: Phase 2 readout est. (NCT06979596)
DESCRIPTION:Opevesostat\, phase 2.\nStudy: A Study of MK-5684 in People Wit
 h Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary completi
 on: 4 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 opevesostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06979596
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821944-1048@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT07821944)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: A Clinical Study of Enlicitide (MK-0616) in Adults Wit
 h Hyperlipidemia in India (MK-0616-038)\nEstimated primary completion: 26 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlici
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07821944
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642780-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05642780)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 in Combinatio
 n With Pembrolizumab in Subjects With Selected Solid Tumors\nEstimated pri
 mary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05642780
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850609-1010@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Alimatravir: Phase 2 readout est. (NCT07850609)
DESCRIPTION:Alimatravir\, phase 2\, HIV.\nStudy: A Clinical Study of Alimat
 ravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on G
 ender-affirming Hormone Therapy and at Low Likelihood of Human Immunodefic
 iency Virus (HIV)-1 Exposure (MK-8527-018)\nEstimated primary completion: 
 2 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alim
 atravir#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07850609
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890884-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT06890884)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab
  Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) Versus Polat
 uzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DL
 BCL) (MK-2140-011/waveLINE-011)\nEstimated primary completion: 13 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-v
 edotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06890884
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854509-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07854509)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI F
 ailure\nEstimated primary completion: 30 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07854509
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253651-2271@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 3 readout est. (NCT05253651)
DESCRIPTION:Tucatinib\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 atinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in 
 First-line HER2+ Metastatic Colorectal Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05253651
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341100-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07341100)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Study to Evaluate th
 e Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the P
 K of SKB264 in OC\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07341100
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307431-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280108
DTEND;VALUE=DATE:20280109
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06307431)
DESCRIPTION:Intismeran Autogene\, phase 2.\nStudy: A Study of Adjuvant Inti
 smeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004
 ).\nEstimated primary completion: 8 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06307431
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132958-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06132958)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy
  Endometrial Cancer (MK-2870-005)\nEstimated primary completion: 10 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-t
 irumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06132958
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230405-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:SKB571: Phase 2 readout est. (NCT07230405)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study of SKB571 in Patient
 s With Lung Cancer\nEstimated primary completion: 19 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07230405
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345729-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Calderasib: Phase 3 readout est. (NCT06345729)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants W
 ith KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Ce
 ll Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004
 /KANDLELIT-004)\nEstimated primary completion: 24 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06345729
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 acituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus 
 Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With 
 Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50
 % (MK-2870-007)\nEstimated primary completion: 25 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06170788
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study in Participants With Advanced Cancers Associated With Express
 ion of DLL3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04471727
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203210-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06203210)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Small Cell Lung Cancer.\nStud
 y: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
  in Subjects With Relapsed Small Cell Lung Cancer\nEstimated primary compl
 etion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06203210
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02332668-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02332668)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of Pe
 mbrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tum
 or or Lymphoma (MK-3475-051/KEYNOTE-051)\nEstimated primary completion: 2 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02332668
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818643-11234@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT06818643)
DESCRIPTION:MK-3120\, phase 1/2.\nStudy: A Study to Evaluate the Safety and
  Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-0
 02)\nEstimated primary completion: 8 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/mk-3120#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06818643
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814066-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SKB571: Phase 2 readout est. (NCT07814066)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Multicenter\, Open-label\, Phase II
  Umbrella Study to Evaluate the Efficacy and Safety of the Investigational
  Product in Participants With Advanced or Metastatic Pancreatic Cancer\nEs
 timated primary completion: 28 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07814066
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161025-2696@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Raludotatug Deruxtecan: Phase 2/3 readout est. (NCT06161025)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2/3.\nStudy: A Study of Raludota
 tug Deruxtecan (R-DXd) in Subjects With Platinum-resistant\, High-grade Ov
 arian\, Primary Peritoneal\, or Fallopian Tube Cancer\nEstimated primary c
 ompletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/raludotatug-deruxtecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06161025
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfort
 umab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Ca
 rcinoma (MK-3475-04C/KEYMAKER-U04)\nEstimated primary completion: 31 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648
 3334
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041802-2259@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 2 reado
 ut est. (NCT06041802)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 2.
 \nStudy: A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (P
 embrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese
  Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcino
 ma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)\nE
 stimated primary completion: 31 March 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06041802
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324629-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07324629)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Participants With Locally Advanced or Metastatic Thymic Carcinoma\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07324629
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Substudy 06D: Combin
 ation Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-34
 75-06D/Keymaker-U06)\nEstimated primary completion: 9 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-11235@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Opevesostat\, phase 3\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Opevesostat (MK-5684) Versus Alternative Next
 -generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prosta
 te Cancer (mCRPC) Post One NHA (MK-5684-004)\nEstimated primary completion
 : 10 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/opeves
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06136650
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644781-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06644781)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Esophageal Squamous Cell Carc
 inoma.\nStudy: A Study of Ifinatamab Deruxtecan in Subjects With Pretreate
 d Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate
 -Esophageal01)\nEstimated primary completion: 1 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06644781
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06459180-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06459180)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Trea
 tment of Physician's Choice as Second-line Treatment for Participants With
  Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101
 /ENGOT-cx20)\nEstimated primary completion: 15 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06459180
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925750-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06925750)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)\nEstimated p
 rimary completion: 16 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06925750
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925737-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06925737)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3.\nStudy: A Clinical Study of If
 inatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-
 2400-001)\nEstimated primary completion: 26 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925737
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961006-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06961006)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People Wi
 th Melanoma (V940-012/INTerpath-012)\nEstimated primary completion: 22 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/intismeran-au
 togene#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06961006
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330064-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06330064)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study to Evaluate 
 the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With 
 Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)\nEstimated primar
 y completion: 25 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06330064
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03711032-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03711032)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Muscle Invasive Bladder Cancer.\n
 Study: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With 
 Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Ca
 ncer (HR NMIBC) (MK-3475-676/KEYNOTE-676)\nEstimated primary completion: 3
 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03711032
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697586-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07697586)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07697586
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305754-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06305754)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplat
 in Combination Therapy in Participants With Epidermal Growth Factor (EGFR)
 -Mutated\, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Hav
 e Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06305754
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239741-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05239741)
DESCRIPTION:Pembrolizumab\, phase 3\, Colorectal Cancer.\nStudy: Study of P
 embrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With St
 age IV Colorectal Cancer (MK-3475-C66)\nEstimated primary completion: 19 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05239741
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05587712-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT05587712)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: Study to Evaluate Sotatercept (MK-7962) in Children With Pul
 monary Arterial Hypertension (PAH) (MK-7962-008)\nEstimated primary comple
 tion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05587712
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793942-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07793942)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: A Clinical Trial of MK-
 2010 Alone and With Other Treatments in Participants With Advanced Solid T
 umors (MK-2010-002)\nEstimated primary completion: 26 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07793942
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668154-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SKB571: Phase 2 readout est. (NCT07668154)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study to Evaluate the Effi
 cacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07668154
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492291-1048@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT06492291)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Open-label Extension Study of Enlicitide Decanoate (MK
 -0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia
  (MK-0616-019) CORALreef Extension\nEstimated primary completion: 13 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06492
 291
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430801-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06430801)
DESCRIPTION:tulisokibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Ev
 aluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants W
 ith Moderate to Severe Crohn's Disease (MK-7240-008)\nEstimated primary co
 mpletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06430801
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504394-2259@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 2 reado
 ut est. (NCT06504394)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 2.
 \nStudy: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-
 3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants 
 With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed
  or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475
 A-F65)\nEstimated primary completion: 8 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650439
 4
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375800-960@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281112
DTEND;VALUE=DATE:20281113
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT04375800)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Doravirine (DOR)
  in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <
 12 Years and <45 kg (MK-1439-066)\nEstimated primary completion: 12 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravirine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04375
 800
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-2028@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Olaparib: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Phase III Randomi
 sed Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Tre
 atment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Can
 cer\nEstimated primary completion: 20 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06746116-2028@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olaparib: Phase 3 readout est. (NCT06746116)
DESCRIPTION:Olaparib\, phase 3.\nStudy: A Study to Evaluate the Use of Durv
 alumab in Combination With Platinum-based Chemotherapy Followed by Durvalu
 mab With Olaparib as First-line Treatment in Advanced or Recurrent Endomet
 rial Cancer in Spain\nEstimated primary completion: 30 November 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06746116
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136624-11235@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136624)
DESCRIPTION:Opevesostat\, phase 3.\nStudy: Study of Opevesostat (MK-5684) V
 ersus Alternative NHA in mCRPC (MK-5684-003)\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 pevesostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06136624
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06596694-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06596694)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Study of Patritumab 
 Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HE
 RTHENA-PanTumor02)\nEstimated primary completion: 7 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06596694
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218029-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07218029)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-038)\nEstimated primary completion: 
 7 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sota
 tercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07218029
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SKB571: Phase 2 readout est. (NCT07622186)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Can
 cer (NSCLC)\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04728893-11239@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT04728893)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Efficacy and Safety of Nemtabr
 utinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-00
 3)\nEstimated primary completion: 4 January 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04728893
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT\
 ; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2
 870-023]\nEstimated primary completion: 12 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-2028@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684
 )-Based Treatment Combinations or Opevesostat Alone in Participants With M
 etastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nEsti
 mated primary completion: 15 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266831-965@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Islatravir: Phase 2/3 readout est. (NCT07266831)
DESCRIPTION:Islatravir\, phase 2/3\, HIV.\nStudy: A Clinical Study of Islat
 ravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Befo
 re (MK-8591B-062)\nEstimated primary completion: 1 February 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/islatravir#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07266831
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) an
 d Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory E
 xtensive-Stage Small Cell Lung Cancer (MK-6070-002)\nEstimated primary com
 pletion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06780137
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562830-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05562830)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Sub
 study of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/
 L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (
 MK-3475-04A)\nEstimated primary completion: 26 February 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05562830
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical 
 Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003
 ).\nEstimated primary completion: 27 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997497-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Calderasib: Phase 3 readout est. (NCT06997497)
DESCRIPTION:Calderasib\, phase 3.\nStudy: A Clinical Study of Calderasib (M
 K-1084) With Targeted Therapy and Chemotherapy in People With Colorectal C
 ancer (MK-1084-012/KANDLELIT-012)\nEstimated primary completion: 28 March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/calderasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06997497
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07302347-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07302347)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: A St
 udy of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors 
 or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (M
 K-3475-G21/KEYNOTE-G21)\nEstimated primary completion: 30 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07302347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06395103-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zilovertamab vedotin: Phase 1/2 readout est. (NCT06395103)
DESCRIPTION:Zilovertamab vedotin\, phase 1/2\, Diffuse Large B-Cell Lymphom
 a.\nStudy: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult
  Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/L
 IGHTBEAM-U01)\nEstimated primary completion: 31 March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06395103
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876128-2066@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:SKB571: Phase 1/2 readout est. (NCT07876128)
DESCRIPTION:SKB571\, phase 1/2.\nStudy: A Clinical Trial of MK-2750 in Part
 icipants With Advanced Solid Tumors (MK-2750-002)\nEstimated primary compl
 etion: 12 April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /skb571#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07876128
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406401-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290426
DTEND;VALUE=DATE:20290427
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT05406401)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyc
 lophosphamide\, Doxorubicin\, and Prednisone Plus Rituximab or Rituximab B
 iosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymp
 homa (DLBCL) (MK-2140-007)\nEstimated primary completion: 26 April 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05406
 401
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824467-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06824467)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-28
 70) Maintenance Treatment Versus Standard of Care in Participants With Pla
 tinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov
 84/GOG-3103)\nEstimated primary completion: 27 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06824467
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874815-1526@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ohtuvayre (ensifentrine): Phase 3 readout est. (NCT07874815)
DESCRIPTION:Ohtuvayre (ensifentrine)\, phase 3\, Chronic Obstructive Pulmon
 ary Disease.\nStudy: Ensifentrine (MK-5884) Study for the Prevention of Ch
 ronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a 
 History of Moderate or Severe Exacerbations While Receiving Standard of Ca
 re (SOC) (MK-5884-031/RPL554/ENHANCE-3)\nEstimated primary completion: 29 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensifentr
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07874815
URL:https://assetmemo.bio/drug/ensifentrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07033494-799@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:MK-2214: Phase 2 readout est. (NCT07033494)
DESCRIPTION:MK-2214\, phase 2\, Alzheimer's Disease.\nStudy: A Clinical Stu
 dy of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)\nEsti
 mated primary completion: 30 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/mk-2214#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07033494
URL:https://assetmemo.bio/drug/mk-2214#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458297-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT05458297)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Chronic Lymphocytic Leukemia.\
 nStudy: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Co
 mbination in Participants With Aggressive and Indolent B-cell Malignancies
  (MK-2140-006)\nEstimated primary completion: 17 May 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05458297
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646860-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290524
DTEND;VALUE=DATE:20290525
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07646860)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Study of Sotatercept (MK-7962) in Japanese Children With P
 ulmonary Arterial Hypertension (PAH) (MK-7962-032)\nEstimated primary comp
 letion: 24 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07646860
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776252-10993@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290529
DTEND;VALUE=DATE:20290530
SUMMARY:Doravirine/islatravir (Idvynso): Phase 3 readout est. (NCT04776252)
DESCRIPTION:Doravirine/islatravir (Idvynso)\, phase 3\, HIV.\nStudy: Open-l
 abel\, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Part
 icipants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-0
 33)\nEstimated primary completion: 29 May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04776252
URL:https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861074-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07861074)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Trial Of Tulisokibar
 t In Participants With Active\, Non-Infectious Uveitis (MK-7240-019)\nEsti
 mated primary completion: 5 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07861074
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791732-2696@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07791732)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maint
 enance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer 
 (REJOICE-Ovarian03)\nEstimated primary completion: 1 July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791732
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemother
 apy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEstimate
 d primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Zilovertamab vedotin: Phase 3 readout est. (NCT06717347)
DESCRIPTION:Zilovertamab vedotin\, phase 3\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination Wi
 th Rituximab Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) 
 Versus Rituximab Plus Cyclophosphamide\, Doxorubicin\, Vincristine\, and P
 rednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-214
 0-010)\nEstimated primary completion: 2 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06717347
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419295-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290727
DTEND;VALUE=DATE:20290728
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07419295)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) to Treat Urot
 helial Cancer (MK-2870-031)\nEstimated primary completion: 27 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 419295
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2271@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Disitam
 ab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated primary 
 completion: 28 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06157892
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small C
 ell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07286149
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714085-587@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290820
DTEND;VALUE=DATE:20290821
SUMMARY:Verquvo (Vericiguat): Phase 2/3 readout est. (NCT05714085)
DESCRIPTION:Verquvo (Vericiguat)\, phase 2/3\, Heart Failure.\nStudy: Effic
 acy\, Safety\, and Pharmacokinetics of Vericiguat in Pediatric Participant
 s With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242
 -036)\nEstimated primary completion: 20 August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vericiguat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05714085
URL:https://assetmemo.bio/drug/vericiguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Substudy 06C: A Study of Inv
 estigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Parti
 cipants With First-Line Locally Advanced Unresectable/Metastatic Gastroeso
 phageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated primary compl
 etion: 12 September 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867938-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291005
DTEND;VALUE=DATE:20291006
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07867938)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Trial of Tulisokibar
 t (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)\nEsti
 mated primary completion: 5 October 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07867938
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinic
 al Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestin
 al Cancers (MK-9999-02A)\nEstimated primary completion: 16 October 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933577-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT05933577)
DESCRIPTION:Intismeran Autogene\, phase 3\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-R
 isk Melanoma (V940-001)\nEstimated primary completion: 26 October 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0593357
 7
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: K
 EYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Partici
 pants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Vir
 al Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)\nEst
 imated primary completion: 15 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008756-1048@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291129
DTEND;VALUE=DATE:20291130
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT06008756)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Ca
 rdiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes\nEstimated pr
 imary completion: 29 November 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/enlicitide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06008756
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586943-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07586943)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: SKB118 Injection i
 n Advanced Solid Tumors\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07586
 943
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190248-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Calderasib: Phase 3 readout est. (NCT07190248)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study of Calderasib (MK-1084) and Other Treatments for Participants
  With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)\nEstimated pr
 imary completion: 7 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/calderasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07190248
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938817-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291210
DTEND;VALUE=DATE:20291211
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04938817)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Safety and Efficacy Study of
  Investigational Agents as Monotherapy or in Combination With Pembrolizuma
 b (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (E
 S-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)\nEstimate
 d primary completion: 10 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04938817
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660654-2696@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06660654)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2.\nStudy: A Study of Raludotatu
 g Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOIC
 E-PanTumor01)\nEstimated primary completion: 30 December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06660654
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Study of Patri
 tumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Partic
 ipants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low 
 Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\n
 Estimated primary completion: 31 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839585-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20300108
DTEND;VALUE=DATE:20300109
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07839585)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Heart Failure.\nStudy: A Cl
 inical Study of Sotatercept (MK-7962) in People With Combined Postcapillar
 y and Precapillary Pulmonary Hypertension and Heart Failure With Preserved
  Ejection Fraction (MK-7962-041)\nEstimated primary completion: 8 January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0783958
 5
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: A Study of Sac
 ituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in Combination
  With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast 
 Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 18 May 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06841354
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06077760-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20300625
DTEND;VALUE=DATE:20300626
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06077760)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Ve
 rsus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung C
 ancer (V940-002)\nEstimated primary completion: 25 June 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06077760
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172478-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20301119
DTEND;VALUE=DATE:20301120
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06172478)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 19 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06172478
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (M
 K-2400) in People With Small Cell Lung Cancer (MK-6070-003)\nEstimated pri
 mary completion: 29 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07227597
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Sacituzumab Ti
 rumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achi
 eve pCR (MK-2870-012)\nEstimated primary completion: 16 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06393374
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941272-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06941272)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: A Study of Patrituma
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01C/LIGHTBEAM-U01)\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-d
 eruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06941272
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701941-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07701941)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Patritumab Deruxtecan (HER3-DXd) in Combinatio
 n With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive\, H
 ER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer\nEstimat
 ed primary completion: 1 January 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07701941
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03725059-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310124
DTEND;VALUE=DATE:20310125
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03725059)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Pembr
 olizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemothe
 rapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen
  Receptor-Positive\, Human Epidermal Growth Factor Receptor 2-Negative (ER
 +/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)\nEstimated primary comple
 tion: 24 January 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03725059
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: KEYMA
 KER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfort
 umab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-0
 4D/KEYMAKER-U04)\nEstimated primary completion: 8 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630974-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310817
DTEND;VALUE=DATE:20310818
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07630974)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study of Ifinatama
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01D/LIGHTBEAM-U01)\nEstimated primary completion: 17 August
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-der
 uxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07630974
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2696@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A Cl
 inical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab
  in Participants With Ovarian Cancer Who Have Progressed During Treatment 
 With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGO
 T-ov107/GOG-3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 Au
 gust 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/raludotatu
 g-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07743164
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06833073-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310903
DTEND;VALUE=DATE:20310904
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06833073)
DESCRIPTION:Intismeran Autogene\, phase 2.\nStudy: A Clinical Study of Inti
 smeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INT
 erpath-011)\nEstimated primary completion: 3 September 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06833073
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013487-11240@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310906
DTEND;VALUE=DATE:20310907
SUMMARY:V181: Phase 3 readout est. (NCT07013487)
DESCRIPTION:V181\, phase 3\, Dengue.\nStudy: A Study to Evaluate V181 Dengu
 e Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-
 1)\nEstimated primary completion: 6 September 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/v181#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07013487
URL:https://assetmemo.bio/drug/v181#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785609-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07785609)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Clinical Trial of 
 MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid 
 Tumors (MK-2010)\nEstimated primary completion: 30 September 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07785609
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863272-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06863272)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Clinical Study of 
 Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Tr
 eat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDe
 ate-Prostate02)\nEstimated primary completion: 1 October 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06863272
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049926-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20311026
DTEND;VALUE=DATE:20311027
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT07049926)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : Substudy 03C: A Study of Combination Therapies in Participants With Rena
 l Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Thera
 py (MK-3475-03C/KEYMAKER-U03)\nEstimated primary completion: 26 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07049926
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Pembrolizumab\, phase 3\, Cervical Cancer.\nStudy: A Clinical S
 tudy of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizuma
 b (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-287
 0-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary completion: 29 O
 ctober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07216703
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Pembrolizumab\, phase 3\, Bladder Cancer.\nStudy: A Clinical Tr
 ial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) and Pembrolizumab (MK-3
 475A) in Participants With Bladder Cancer (MK-2870-055)\nEstimated primary
  completion: 17 November 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07829783
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908537-11236@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20311208
DTEND;VALUE=DATE:20311209
SUMMARY:Gocatamig: Phase 3 readout est. (NCT07908537)
DESCRIPTION:Gocatamig\, phase 3\, Small Cell Lung Cancer.\nStudy: A Clinica
 l Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small 
 Cell Lung Cancer (MK-6070-004)\nEstimated primary completion: 8 December 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gocatamig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07908537
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Substudy 06E: Umbrella Study of Combination Therapies in Esophage
 al Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion: 4 Janu
 ary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6780111
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small
  Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated primary co
 mpletion: 6 February 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK
 -3475) With or Without Chemotherapy When Used With Investigational Agents 
 in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer 
 (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 13 Febr
 uary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04165070
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227402-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320227
DTEND;VALUE=DATE:20320228
SUMMARY:Welireg (Belzutifan): Phase 3 readout est. (NCT07227402)
DESCRIPTION:Welireg (Belzutifan)\, phase 3\, Renal Cell Carcinoma.\nStudy: 
 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent 
 Kidney Cancer Following Adjuvant Therapy (MK-6482-033)\nEstimated primary 
 completion: 27 February 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07227402
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Substudy 01I: A Study of Investigational Agents in Participants Wit
 h Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) 
 (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678
 0098
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2527@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Investigational Agents in Participants With Previously T
 reated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01
 H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Pembrolizumab With or Without Chemotherapy in Combination With A
 dditional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3
 475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06731907
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2696@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Ma
 intenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-0
 06\, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary complet
 ion: 19 March 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 aludotatug-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07776691
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209111-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320409
DTEND;VALUE=DATE:20320410
SUMMARY:Calderasib: Phase 2 readout est. (NCT07209111)
DESCRIPTION:Calderasib\, phase 2.\nStudy: A Clinical Study of Calderasib (M
 K-1084) in People With Advanced Solid Tumors (MK-1084-014)\nEstimated prim
 ary completion: 9 April 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/calderasib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07209111
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: A Study t
 o Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizu
 mab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With
  Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GO
 G-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06952504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947851-11239@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320601
DTEND;VALUE=DATE:20320602
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05947851)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) i
 n Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemi
 a/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).\nEstima
 ted primary completion: 1 June 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05947851
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722611-2890@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320625
DTEND;VALUE=DATE:20320626
SUMMARY:Bomedemstat: Phase 2/3 readout est. (NCT07722611)
DESCRIPTION:Bomedemstat\, phase 2/3.\nStudy: A Clinical Trial of Bomedemsta
 t in Participants With Polycythemia Vera (MK-3543-025).\nEstimated primary
  completion: 25 June 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bomedemstat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07722611
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Metastatic Castration-Res
 istant Prostate Cancer.\nStudy: MK-2870-U01 Substudy 1: A Clinical Trial o
 f Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)\nEstimate
 d primary completion: 29 June 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07908524
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Patritumab Deruxtecan With Other Anticancer Agents in Participants Wi
 th HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Re
 moved (MK-1022-009)\nEstimated primary completion: 2 August 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136559-11239@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20320907
DTEND;VALUE=DATE:20320908
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT06136559)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choi
 ce of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic L
 eukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
 \nEstimated primary completion: 7 September 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06136559
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04924075-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20321118
DTEND;VALUE=DATE:20321119
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT04924075)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Belzutifan/MK-6482 for 
 the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)\, Pancreat
 ic Neuroendocrine Tumor (pNET)\, Von Hippel-Lindau (VHL) Disease-Associate
 d Tumors\, Advanced Gastrointestinal Stromal Tumor (wt GIST)\, or Solid Tu
 mors With HIF-2α Related Genetic Alterations (MK-6482-015)\nEstimated pri
 mary completion: 18 November 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04924075
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897881-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20321121
DTEND;VALUE=DATE:20321122
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT03897881)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: An Efficacy S
 tudy of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 
 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)\nE
 stimated primary completion: 21 November 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03897881
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554339-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20321215
DTEND;VALUE=DATE:20321216
SUMMARY:Calderasib: Phase 3 readout est. (NCT07554339)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Sma
 ll Cell Lung Cancer (MK-1084-015/KANDLELIT-015)\nEstimated primary complet
 ion: 15 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/calderasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07554339
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318558-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20330225
DTEND;VALUE=DATE:20330226
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07318558)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A C
 linical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian 
 Cancer (MK-2870-021)\nEstimated primary completion: 25 February 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318
 558
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-1991@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A Cl
 inical Study of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With
  Breast Cancer (MK-2870-032)\nEstimated primary completion: 23 March 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumote
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06966700
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623422-2042@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20330516
DTEND;VALUE=DATE:20330517
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06623422)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogen
 e (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpa
 th-009)\nEstimated primary completion: 16 May 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06623422
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060807-1981@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20330714
DTEND;VALUE=DATE:20330715
SUMMARY:Patritumab Deruxtecan: Phase 3 readout est. (NCT07060807)
DESCRIPTION:Patritumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Clinical Study of Patritumab Deruxtecan to Treat Breast C
 ancer (MK-1022-016)\nEstimated primary completion: 14 July 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07060807
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058077-1048@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20331204
DTEND;VALUE=DATE:20331205
SUMMARY:Lipfendra (Enlicitide): Phase 2/3 readout est. (NCT07058077)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 2/3\, Atherosclerotic Cardiovasc
 ular Disease.\nStudy: A Study of Enlicitide Decanoate (MK-0616\, an Oral P
 CSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hyp
 ercholesterolemia (MK-0616-029)\nEstimated primary completion: 4 December 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07058077
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700758-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20340102
DTEND;VALUE=DATE:20340103
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07700758)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: A Study of Belzutifan i
 n Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)\nE
 stimated primary completion: 2 January 2034. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07700758
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess Efficacy and Safety of Pembrolizumab With or Without Saci
 tuzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non S
 mall Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response
  (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 2034. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06312137
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405164-11244@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20340422
DTEND;VALUE=DATE:20340423
SUMMARY:Welireg (Belzutifan): Phase 3 readout est. (NCT07405164)
DESCRIPTION:Welireg (Belzutifan)\, phase 3.\nStudy: Extension Study for Par
 ticipants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)\n
 Estimated primary completion: 22 April 2034. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07405164
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07513376)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizuma
 b Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
  Non-Small Cell Lung Cancer (V940-014)\nEstimated primary completion: 22 A
 ugust 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07513376
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351631-2890@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20341204
DTEND;VALUE=DATE:20341205
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06351631)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)\nEstimate
 d primary completion: 4 December 2034. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06351631
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06814145-534@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20350810
DTEND;VALUE=DATE:20350811
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06814145)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2.\nStudy: Extension Study of S
 otatercept in People With Pulmonary Hypertension (MK-7962-023)\nEstimated 
 primary completion: 10 August 2035. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06814145
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917754-9128@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20370313
DTEND;VALUE=DATE:20370314
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT07917754)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Partic
 ipants With Diffuse Large B-cell Lymphoma (MK-1045-010)\nEstimated primary
  completion: 13 March 2037. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zilovertamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07917754
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651281-2@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20371217
DTEND;VALUE=DATE:20371218
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06651281)
DESCRIPTION:tulisokibart\, phase 3\, Ulcerative Colitis.\nStudy: Extension 
 Study of Long-term Safety and Efficacy of Tulisokibart in Participants Wit
 h Crohn's Disease or Ulcerative Colitis (MK-7240-011)\nEstimated primary c
 ompletion: 17 December 2037. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651281
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431827-1988@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20391026
DTEND;VALUE=DATE:20391027
SUMMARY:Calderasib: Phase 3 readout est. (NCT07431827)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MK-3
 475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS
  G12Cm NSCLC (MK-1084-013)\nEstimated primary completion: 26 October 2039.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07431827
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-1973@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03486873)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Long-term Safet
 y and Efficacy Extension Study for Participants With Advanced Tumors Who A
 re Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Stu
 dy (MK-3475-587/KEYNOTE-587)\nEstimated primary completion: 4 August 2043.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
